Researchers identified a unique protein signature in the blood of BMD and LGMD patients that may reflect disease progression.

Ifetroban improved heart function and reduced cardiac damage biomarkers in people with DMD in a Phase 2 clinical trial.

Summer can be rough for folks with muscular dystrophy, columnist Patrick Moeschen writes, but it can also bring adventures in appreciation.

The FDA has granted rare pediatric disease designation to PBGENE-DMD, an experimental gene-editing therapy for Duchenne ...

The U.S. Food and Drug Administration is due to review data on deramiocel, a cell therapy up for approval for heart disease ...

A recent dream leaves columnist Robin Stemple questioning how his disability progression due to FSHD affects his family and ...

Understanding how corticosteroids work, when they’re typically started, and how their side effects are managed can help people living with DMD and their caregivers make informed decisions about taking ...

A recent concert in Singapore was all about finding harmony through the talents that unite us in life, writes columnist.

Living with muscular dystrophy can be challenging, and there are considerations that must be taken into account on a day-to-basis and in certain situations to help patients manage the disease. Many ...

Approved exon-skipping therapies Exondys 51 Exondys 51 (eteplirsen) was developed by Sarepta Therapeutics as a treatment for DMD patients with mutations amenable to exon 51 skipping. That’s about 13% ...